Current treatment of non-alcoholic fatty liver disease

Ahmed, Mohamed H. and Byrne, Christopher D. (2008) Current treatment of non-alcoholic fatty liver disease Diabetes, Obesity and Metabolism, 11, (3), pp. 188-195. (doi:10.1111/j.1463-1326.2008.00926.x).


[img] PDF DOM._NAFLD._PMID_18564173.pdf - Version of Record
Restricted to Repository staff only

Download (104kB)


Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease in Western World and frequently associated with insulin resistance and overweight and occurs often with type 2 diabetes. Interestingly, NAFLD is not only regarded as a hepatic component of the metabolic syndrome but also as an independent risk factor and a marker for increase in cardiovascular disease (CVD). Significantly, NAFLD is associated with an increased risk of all-cause mortality and predicts future CVD events independent of age, sex, LDL-cholesterol and features of metabolic syndrome. Although there was initial concern about drug toxicity with NAFLD, increasing evidence suggests that commonly used drugs such as metformin and statins do not cause harm and the thiazolidinediones (TZDs) may even confer a therapeutic benefit in NAFLD. Interestingly, medical and surgical treatments of obesity show potential benefit in treating NAFLD. In this review, we have focused on the safety and therapeutic impact of TZDs, statins, metformins and obesity medications in NAFLD. The potential benefit of bariatric surgery and the role of weight loss per se in treating NAFLD are also discussed.

Item Type: Article
Digital Object Identifier (DOI): doi:10.1111/j.1463-1326.2008.00926.x
ISSNs: 1462-8902 (print)
Related URLs:
Keywords: bariatric surgery, insulin resistance, lifestyle, non-alcoholic fatty liver disease, obesity, treatment
ePrint ID: 60863
Date :
Date Event
28 June 2008Published
Date Deposited: 23 Sep 2008
Last Modified: 16 Apr 2017 17:32
Further Information:Google Scholar

Actions (login required)

View Item View Item